Rationale and design of PRIMA II: A multicenter, randomized clinical trial to study the impact of in-hospital guidance for acute decompensated heart failure treatment by a predefined NT-PRoBNP target on the reduction of readmIssion and Mortality rAtes.

Am Heart J 2014 Jul 23;168(1):30-6. Epub 2014 Apr 23.

Department of Cardiology, Academic Medical Center, Amsterdam, The Netherlands. Electronic address:

Background: Hospital admissions for acute decompensated heart failure (ADHF) are frequent and are accompanied by high percentages of mortality and readmissions. Brain natriuretic peptide (BNP) and the inactive N-terminal fragment of its precursor proBNP (NT-proBNP) are currently the best predictors of prognosis in heart failure (HF) patients. In the setting of chronic HF, studies that performed guidance of therapy by NT-proBNP have had only limited success. For patients with ADHF, retrospective studies have shown that a reduction in NT-proBNP of ≤30% during admission is a significant predictor of HF readmissions and mortality. These data suggest a role for NT-proBNP guidance in the setting of ADHF admissions.

Study Design: The PRIMA II is an investigator-initiated, multicenter, randomized, controlled, prospective 2-arm trial that investigates the impact of inhospital guidance for ADHF treatment by a predefined NT-proBNP target (>30% reduction during admission) on the reduction of readmission and mortality rates within 180 days. Consenting ADHF patients with NT-proBNP levels of >1,700 ng/L are eligible. After achieving clinical stability, a total of 340 patients are randomized to either NT-proBNP-guided or conventional treatment (1:1). The primary end point is dual, that is, a composite of all-cause mortality and readmission for HF in 180 days and the number of days alive out of hospital in 180 days. Secondary end points are readmissions and/or mortality in 180 days, cost effectiveness of hospitalization days in 180 days, readmissions and mortality in 90 days, and quality of life.

Conclusion: The PRIMA II trial aims at providing scientific evidence for the use of NT-proBNP-guided therapy compared with conventional treatment in patients admitted for ADHF.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2014.04.008DOI Listing
July 2014
39 Reads

Publication Analysis

Top Keywords

180 days
20
heart failure
12
reduction readmission
8
readmission mortality
8
nt-probnp target
8
treatment predefined
8
decompensated heart
8
acute decompensated
8
predefined nt-probnp
8
mortality rates
8
design prima
8
days
8
readmissions mortality
8
conventional treatment
8
multicenter randomized
8
nt-probnp
7
mortality
7
adhf
6
0
5
patients
5

Altmetric Statistics

Similar Publications